Next-Generation Direct-Acting Antiviral Drug-Based Regimens for Hepatitis C

Next-Generation Direct-Acting Antiviral Drug-Based Regimens for Hepatitis C Curr Hepatology Rep (2017) 16:184–191 DOI 10.1007/s11901-017-0351-0 HEPATITIS C (J AHN AND A ARONSOHN, SECTION EDITORS) Next-Generation Direct-Acting Antiviral Drug-Based Regimens for Hepatitis C 1,2 1,3,4 1,3,4 Isaac Ruiz & Stéphane Chevaliez & Jean-Michel Pawlotsky Published online: 25 July 2017 Springer Science+Business Media, LLC 2017 Abstract to-use, highly efficient, pangenotypic, once-daily, all-oral, Purpose of Review This article reviews the most recent results interferon- and ribavirin-free. of clinical trials supporting the approval and use of the so-called . . next-generation hepatitis C virus (HCV) direct-acting antiviral Keywords Hepatitis C virus Direct-acting antiviral drugs (DAA) drug regimens, including glecaprevir/pibrentasvir, Next-generation regimens Resistance-associated sofosbuvir/velpatasvir/voxilaprevir, uprifosbuvir/grazoprevir/ substitutions ruzasvir, and AL-335/simeprevir/odalasvir. Recent Findings From 2014 and onwards, HCV DAA drugs belonging to four classes were approved in Europe and the Introduction USA. These combinations are generally safe and well tolerat- ed and yield high rates of sustained virological response Hepatitis C virus (HCV) infection represents a major public (>95%) in most patient populations. However, there is a need health problem, with over 71 million persons chronically infect- for treatment simplification and efficacy in difficult-to-cure ed worldwide [1� ]. The primary goal of HCV therapy is to cure patient populations. Phase II and III clinical Current Hepatology Reports Springer Journals

Next-Generation Direct-Acting Antiviral Drug-Based Regimens for Hepatitis C

Loading next page...
Springer US
Copyright © 2017 by Springer Science+Business Media, LLC
Medicine & Public Health; Hepatology
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial